lamotrigine has been researched along with Diplopia in 6 studies
Diplopia: A visual symptom in which a single object is perceived by the visual cortex as two objects rather than one. Disorders associated with this condition include REFRACTIVE ERRORS; STRABISMUS; OCULOMOTOR NERVE DISEASES; TROCHLEAR NERVE DISEASES; ABDUCENS NERVE DISEASES; and diseases of the BRAIN STEM and OCCIPITAL LOBE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate and compare the effects of concomitant lamotrigine (LTG) or carbamazepine (CBZ) on the incidence of treatment-emergent adverse events (TEAEs) in patients taking adjunctive eslicarbazepine acetate (ESL) for focal (partial-onset) seizures (FS)." | 9.27 | Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures. ( Abou-Khalil, B; Blum, D; Cheng, H; Gama, H; Grinnell, T; Jung, J; Klein, P; Rocha, F; Ryvlin, P; Shah, A; Specchio, LM, 2018) |
| " Headache, drowsiness, faintness, and diplopia, the common adverse events (AEs), were mild to moderate in intensity and occurred in 50-75% of patients in both groups (except for diplopia, occurring only with LTG)." | 6.68 | Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study. ( Gay, P; Lai, AA; Madsen, J; Matsuo, F; Risner, ME; Rollins, DE; Tolman, KG, 1996) |
| "To evaluate and compare the effects of concomitant lamotrigine (LTG) or carbamazepine (CBZ) on the incidence of treatment-emergent adverse events (TEAEs) in patients taking adjunctive eslicarbazepine acetate (ESL) for focal (partial-onset) seizures (FS)." | 5.27 | Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures. ( Abou-Khalil, B; Blum, D; Cheng, H; Gama, H; Grinnell, T; Jung, J; Klein, P; Rocha, F; Ryvlin, P; Shah, A; Specchio, LM, 2018) |
| "To determine the effects of lamotrigine on (1) seizures, (2) adverse-effect profile, and (3) cognition and quality of life, compared to placebo, when used as an add-on treatment for people with drug-resistant focal epilepsy." | 5.05 | Lamotrigine add-on therapy for drug-resistant focal epilepsy. ( Bresnahan, R; Marson, AG; Panebianco, M; Ramaratnam, S, 2020) |
| " Headache, drowsiness, faintness, and diplopia, the common adverse events (AEs), were mild to moderate in intensity and occurred in 50-75% of patients in both groups (except for diplopia, occurring only with LTG)." | 2.68 | Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study. ( Gay, P; Lai, AA; Madsen, J; Matsuo, F; Risner, ME; Rollins, DE; Tolman, KG, 1996) |
| "05) change in the serum concentrations of either CBZ or its epoxide metabolite when LTG was added either to the group as a whole or to the nine patients who experienced adverse CNS effects." | 1.30 | Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? ( Berry, DJ; Besag, FM; Newbery, JE; Pool, F; Subel, B, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Panebianco, M | 1 |
| Bresnahan, R | 1 |
| Ramaratnam, S | 1 |
| Marson, AG | 2 |
| Androsova, G | 1 |
| Krause, R | 1 |
| Borghei, M | 1 |
| Wassenaar, M | 1 |
| Auce, P | 1 |
| Avbersek, A | 1 |
| Becker, F | 1 |
| Berghuis, B | 1 |
| Campbell, E | 1 |
| Coppola, A | 1 |
| Francis, B | 1 |
| Wolking, S | 1 |
| Cavalleri, GL | 1 |
| Craig, J | 1 |
| Delanty, N | 1 |
| Koeleman, BPC | 1 |
| Kunz, WS | 1 |
| Lerche, H | 1 |
| Sander, JW | 1 |
| Sills, GJ | 1 |
| Striano, P | 1 |
| Zara, F | 1 |
| Sisodiya, SM | 1 |
| Depondt, C | 1 |
| Abou-Khalil, B | 1 |
| Klein, P | 1 |
| Shah, A | 1 |
| Ryvlin, P | 1 |
| Specchio, LM | 1 |
| Gama, H | 1 |
| Rocha, F | 1 |
| Blum, D | 1 |
| Grinnell, T | 1 |
| Cheng, H | 1 |
| Jung, J | 1 |
| Matsuo, F | 2 |
| Gay, P | 1 |
| Madsen, J | 1 |
| Tolman, KG | 1 |
| Rollins, DE | 1 |
| Risner, ME | 1 |
| Lai, AA | 1 |
| Besag, FM | 1 |
| Berry, DJ | 1 |
| Pool, F | 1 |
| Newbery, JE | 1 |
| Subel, B | 1 |
2 reviews available for lamotrigine and Diplopia
| Article | Year |
|---|---|
Lamotrigine add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Ataxia; Child; Cognition; Cross-Over Studies; Diplopia; Dizziness; Drug Resi | 2020 |
Lamotrigine.
Topics: Adolescent; Adult; Animals; Anticonvulsants; Child; Clinical Trials as Topic; Diplopia; Dizziness; D | 1999 |
2 trials available for lamotrigine and Diplopia
| Article | Year |
|---|---|
Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Dibenzazepines; Diplopia; Dose-Response Re | 2018 |
Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study.
Topics: Adolescent; Adult; Anticonvulsants; Diplopia; Dose-Response Relationship, Drug; Double-Blind Method; | 1996 |
2 other studies available for lamotrigine and Diplopia
| Article | Year |
|---|---|
Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis.
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Ataxia; Benzodiazepines; Carbamazepine; Clobazam; | 2017 |
Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?
Topics: Anticonvulsants; Carbamazepine; Child; Diplopia; Dizziness; Dose-Response Relationship, Drug; Drug A | 1998 |